Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicinePolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

Patients with intermediate- or high-risk DLBCL who had not previously received treatment were enrolled in this double-blind, placebo-controlled, international phase 3 trial to compare the modified R-CHOP regimen (pola-R-CHP) to standard R-CHOP. The researchers found that among these patients, the risk of disease progression, relapse, or death was lower among the modified R-CHOP patients.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form